and (tozinameran / riltozinameran)
and (tozinameran / famtozinameran)
and (raxtozinameran))

Search Comirnaty COVID-19 mRNA Vaccines medical information:

Search PREVENAR 13 Medical Information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

Comirnaty COVID-19 mRNA Vaccines Quick Finder

The latest version of the Summary of Product Characteristics (SPC) for COMIRNATY forms can be accessed below:
Formulations for adults and adolescents ≥12 years:
  • 15/15 μg/dose tozinameran/riltozinameran (Original/Omicron BA.1), ready-to-use, grey cap: SPC
  • 15/15 μg/dose tozinameran/famtozinameran (Original/Omicron BA.4-5), ready-to-use, grey cap:  SPC
  • 30 μg/dose tozinameran, ready-to-use, grey cap: SPC
  • 30 μg/dose tozinameran, dilution required, purple cap: SPC
Pediatric formulations: 
  • For infants and children aged 6 months to 4 years: 3 μg/dose tozinameran, dilution required, maroon cap:  SPC
  • For children aged 5 to 11 years: 10 μg/dose tozinameran, dilution required, orange cap:  SPC
  • For children aged 5 to 11 years: 5/5 µg/dose tozinameran/famtozinameran (Original/Omicron BA.4-5), dilution required, orange cap: SPC


Didn’t find what you were looking for? 

Contact us

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Call 1 800 633 363*

*Contact Medical Information between 9 AM and 5 PM Monday to Friday (excluding holidays)

Report Adverse Event

Reporting of Adverse Events

Suspected adverse events should be reported to the Health Products Regulatory Authority (HPRA). Suspected adverse events can also be reported to Pfizer on 1 800 633 363.